These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11074741)

  • 1. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease.
    Hebert PR; Hennekens CH
    Arch Intern Med; 2000 Nov; 160(20):3123-7. PubMed ID: 11074741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
    Berger JS; Krantz MJ; Kittelson JM; Hiatt WR
    JAMA; 2009 May; 301(18):1909-19. PubMed ID: 19436018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
    Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
    JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
    De Schryver EL; Algra A; van Gijn J
    Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on aspirin in the primary prevention of cardiovascular disease.
    Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
    Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of cardiovascular disease: risks and benefits of aspirin.
    Buring JE; Hennekens CH
    J Gen Intern Med; 1990; 5(5 Suppl):S54-7. PubMed ID: 2231066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin in the treatment and prevention of cardiovascular disease.
    Gaziano JM; Skerrett PJ; Buring JE
    Haemostasis; 2000; 30 Suppl 3():1-13. PubMed ID: 11182624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
    JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
    ; Baigent C; Blackwell L; Collins R; Emberson J; Godwin J; Peto R; Buring J; Hennekens C; Kearney P; Meade T; Patrono C; Roncaglioni MC; Zanchetti A
    Lancet; 2009 May; 373(9678):1849-60. PubMed ID: 19482214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
    Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
    Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
    Hankey GJ; Sudlow CL; Dunbabin DW
    Cochrane Database Syst Rev; 2000; (2):CD001246. PubMed ID: 10796426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force.
    Guirguis-Blake JM; Evans CV; Senger CA; O'Connor EA; Whitlock EP
    Ann Intern Med; 2016 Jun; 164(12):804-13. PubMed ID: 27064410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of aspirin use and primary prevention of cardiovascular disease in women.
    Manson JE; Stampfer MJ; Colditz GA; Willett WC; Rosner B; Speizer FE; Hennekens CH
    JAMA; 1991 Jul 24-31; 266(4):521-7. PubMed ID: 2061978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial.
    Ridker PM; Manson JE; Gaziano JM; Buring JE; Hennekens CH
    Ann Intern Med; 1991 May; 114(10):835-9. PubMed ID: 2014943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.
    Xie M; Shan Z; Zhang Y; Chen S; Yang W; Bao W; Rong Y; Yu X; Hu FB; Liu L
    PLoS One; 2014; 9(10):e90286. PubMed ID: 25360605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.
    Leonardi-Bee J; Bath PM; Bousser MG; Davalos A; Diener HC; Guiraud-Chaumeil B; Sivenius J; Yatsu F; Dewey ME;
    Stroke; 2005 Jan; 36(1):162-8. PubMed ID: 15569877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.